Zoetis Inc. (ZTS)

78.79 3.46 (4.59%)

As of 2026-10-15 14:21:25 EST

Zoetis Inc. (/zō-EH-tis/), headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.

Traded asNYSE: ZTS
ISINUS98978V1035
CIK0001555280
LEI549300HD9Q1LOC9KLJ48
EIN460696167
SectorPharmaceutical
IndustryPharmaceutical Preparations
CEOKristin Peck
Employees14,500
Fiscal Year End1231
Address10 SYLVAN WAY, PARSIPPANY, NJ, 07054
Phone973-822-7000
Websitehttp://zoetis.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ZTSZoetis Inc.2026-10-15 14:21:2578.793.464.59
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ZTS0001555280Zoetis Inc.US98978V1035549300HD9Q1LOC9KLJ48460696167NYSE2834Pharmaceutical Preparations1231—10 SYLVAN WAYPARSIPPANYNJ07054UNITED STATESUS973-822-700010 SYLVAN WAY, PARSIPPANY, NJ, 0705410 SYLVAN WAY, PARSIPPANY, NJ, 07054—Pharmaceutical1952Kristin Peck14,500http://zoetis.com69,233,000,000501,891,243413,223,602Zoetis Inc. (/zō-EH-tis/), headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.2026-10-09 00:58:54
This is a preview of the latest data. Subscribe to access the full data.
ZTS Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ZTS Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202569,233,000,000-9,440,000,000-11.999422,127,709-25,664,208-5.7313
202478,673,000,000-673,000,000-0.8482447,791,917-10,075,198-2.2005
202379,346,000,000-1,204,000,000-1.4947457,867,115-5,519,601-1.1911
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Kristin C. PeckChief Executive Officer20211,200,00006,929,7972,340,000318,72413,098,491
Catherine A. KnuppPresident, EVP2021710,00001,368,661852,000168,3763,555,260
Roman TrawickiPresident, EVP2021675,00001,049,922842,400401,4193,318,727
Heidi C. ChenGeneral Counsel, EVP, Corporate Secretary2021615,0000993,543645,750133,8612,719,382
Catherine A. KnuppPresident, EVP2020710,00001,349,924658,880137,0973,305,884
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202514,500
202413,800
202314,100
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue9,467,000,0009,256,000,0008,544,000,000
Cost Of Revenue2,666,000,0002,719,000,0002,561,000,000
Gross Profit6,801,000,0006,537,000,0005,983,000,000
Research And Development Expenses698,000,000686,000,000614,000,000
General And Administrative Expenses2,378,000,0002,318,000,0002,151,000,000
Operating Expenses3,441,000,0003,404,000,0003,047,000,000
Operating Income3,360,000,0003,133,000,0002,936,000,000
Net Income2,673,000,0002,486,000,0002,344,000,000
Earnings Per Share Basic6.035.475.08
Earnings Per Share Diluted6.025.475.07
Weighted Average Shares Outstanding Basic443,443,000454,200,000461,172,000
Weighted Average Shares Outstanding Diluted443,835,000454,848,000462,269,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents2,312,000,0001,987,000,0002,041,000,000
Marketable Securities Current———
Accounts Receivable1,590,000,0001,316,000,0001,304,000,000
Inventories2,430,000,0002,306,000,0002,564,000,000
Non Trade Receivables69,000,00079,000,00058,000,000
Other Assets Current436,000,000377,000,000434,000,000
Total Assets Current6,768,000,0005,986,000,0006,343,000,000
Marketable Securities Non Current———
Property Plant And Equipment3,681,000,0003,391,000,0003,204,000,000
Other Assets Non Current328,000,000250,000,000206,000,000
Total Assets Non Current8,699,000,0008,251,000,0007,943,000,000
Total Assets15,467,000,00014,237,000,00014,286,000,000
Accounts Payable487,000,000433,000,000411,000,000
Deferred Revenue———
Short Term Debt003,000,000
Other Liabilities Current107,000,000125,000,000102,000,000
Total Liabilities Current2,235,000,0003,412,000,0001,889,000,000
Long Term Debt9,042,000,0005,220,000,0006,564,000,000
Other Liabilities Non Current248,000,000222,000,000237,000,000
Total Liabilities Non Current9,901,000,0006,055,000,0007,406,000,000
Total Liabilities12,136,000,0009,467,000,0009,295,000,000
Common Stock5,000,0005,000,0005,000,000
Retained Earnings13,744,000,00011,968,000,00010,295,000,000
Accumulated Other Comprehensive Income-834,000,000-940,000,000-839,000,000
Total Shareholders Equity3,331,000,0004,770,000,0004,997,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization487,000,000497,000,000491,000,000
Share Based Compensation Expense83,000,00074,000,00060,000,000
Other Non Cash Income Expense8,000,0006,000,0008,000,000
Change In Accounts Receivable236,000,00061,000,000102,000,000
Change In Inventories199,000,00040,000,000361,000,000
Change In Non Trade Receivables———
Change In Other Assets165,000,000-52,000,00095,000,000
Change In Accounts Payable46,000,00031,000,00013,000,000
Change In Other Liabilities85,000,000114,000,00067,000,000
Cash From Operating Activities2,904,000,0002,953,000,0002,353,000,000
Purchases Of Marketable Securities7,000,0005,000,0004,000,000
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment621,000,000655,000,000732,000,000
Acquisition Of Business———
Other Investing Activities-1,000,0003,000,000-2,000,000
Cash From Investing Activities-748,000,000-315,000,000-777,000,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends897,000,000812,000,000716,000,000
Issuance Of Common Stock———
Repurchase Of Common Stock3,235,000,0001,858,000,0001,092,000,000
Issuance Of Long Term Debt1,848,000,00000
Repayment Of Long Term Debt1,350,000,00001,350,000,000
Other Financing Activities-3,000,000——
Cash From Financing Activities-1,870,000,000-2,660,000,000-3,109,000,000
Change In Cash325,000,000-54,000,000-1,540,000,000
Cash At End Of Period2,312,000,0001,987,000,0002,041,000,000
Income Taxes Paid715,000,000892,000,000754,000,000
Interest Paid261,000,000274,000,000295,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share6.035.475.08
Price To Earnings Ratio20.865729.786138.8524
Earnings Growth Rate10.23777.677212.6386
Price Earnings To Growth Ratio2.03813.87983.0741
Book Value Per Share7.511710.50210.8224
Price To Book Ratio16.749915.514218.2371
Ebitda4,097,000,0004,100,000,0003,828,000,000
Enterprise Value62,523,998,26077,235,806,00095,547,517,640
Dividend Yield0.01610.0110.0079
Dividend Payout Ratio0.33560.32660.3055
Debt To Equity Ratio2.71451.09431.3142
Capital Expenditures777,000,000684,000,000942,000,000
Free Cash Flow2,127,000,0002,269,000,0001,411,000,000
Return On Equity0.80250.52120.4691
One Year Beta0.61870.62371.0077
Three Year Beta0.71330.91720.9525
Five Year Beta0.82930.92150.9436
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Lagano RoxanneExecutive Vice President2026-10-09367A31,314
Nayak Abhay UExecutive Vice President2026-10-09321A5,022
Ferran Astorga JeannetteExecutive Vice President2026-10-0952A2,349
Sarbaugh KeithExecutive Vice President2026-10-09303A2,668
FULLER JULIEExecutive Vice President2026-10-09367A2,480
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Markwayne MullinSenator2025-12-05Sale (Full)2025-11-10Joint$15,001 - $50,000
Markwayne MullinSenator2025-08-12Purchase2024-01-04Self$1,001 - $15,000
Markwayne MullinSenator2025-08-12Purchase2024-01-04Spouse$1,001 - $15,000
Markwayne MullinSenator2025-06-11Purchase2025-05-13Joint$50,001 - $100,000
Markwayne MullinSenator2025-05-12Sale (Full)2025-04-08Joint$15,001 - $50,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2026-10-12CA31Purchase2026-09-18—$1,001 - $15,000
Gilbert Cisneros2026-09-04CA31Sale (Partial)2026-07-17—$1,001 - $15,000
Byron Donalds2026-07-15FL19Purchase2026-06-09—$1,001 - $15,000
Byron Donalds2026-07-15FL19Purchase2026-06-09Spouse$1,001 - $15,000
Gilbert Cisneros2026-07-02CA31Purchase2026-06-16—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
NFSG Corp2026-09-3011,93917169.8187
Activest Wealth Management2026-09-3022,20631869.8302
InTrack Investment Management Inc2026-09-30273,9433,92369.83
HCR Wealth Advisors2026-09-30703,79010,07869.8343
MISSION WEALTH MANAGEMENT, LP2026-09-30238,6273,41769.8352
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2026-08-31Bright Rock Large Cap Fund Institutional Class SharesBQLCX54,0004,163,4000.8864
TRUST FOR PROFESSIONAL MANAGERS2026-08-31Column Mid Cap FundCFMCX2,517194,060.70.0173
Lattice Strategies Trust2026-07-31Hartford Multifactor US Equity ETFROUS2,228172,202.120.0244
HARTFORD MUTUAL FUNDS, INC2026-07-31Class FHBLFX384,20229,694,972.580.2681
HARTFORD MUTUAL FUNDS, INC2026-07-31Class R6HBLVX384,20229,694,972.580.2681
This is a preview of the latest data. Subscribe to access the full data.